Anti-SARS-CoV-2 spike monoclonal antibody
Sotrovimab
Brand names: Xevudy
Adult dose
Dose: 500mg IV single dose (within 5 days of symptom onset)
Route: IV
Frequency: single
Clinical pearls
- Mild-moderate COVID-19 in high-risk groups (CMDU pathway) — efficacy depends on circulating variant
- Variant-dependent activity per NICE TA878 / current guidance
Contraindications
- Hypersensitivity
- Hospitalisation due to COVID-19 oxygen requirement
Side effects
- Infusion reactions
- Anaphylaxis (rare)
- Headache
- Diarrhoea
Interactions
- No clinically significant
Monitoring
- Infusion reactions
Reference: BNF; NICE TA878; UKHSA; https://bnf.nice.org.uk/drugs/sotrovimab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- 4C Mortality Score for COVID-19 · COVID-19
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023